title: Tetramethylpyrazine potentiates arsenic trioxide activity against HL-60 cell lines.
abstract: The objective of this study was to evaluate the effects of tetramethylpyrazine (TMP) in combination with arsenic trioxide (As2O3) on the proliferation and differentiation of HL-60 cells. The HL-60 cells were treated with 300 µg/mL TMP, 0.5 µM As2O3, and 300 µg/mL TMP combined with 0.5 µM As2O3, respectively. The proliferative inhibition rates were determined with MTT. Differentiation was detected by the nitroblue tetrazolium (NBT) reduction test, Wright's staining and the distribution of CD11b and CD14. Flow cytometry was used to analyze cell cycle distribution. RT-PCR and Western blot assays were employed to detect the expressions of c-myc, p27, CDK2, and cyclin E1. Combination treatment had synergistic effects on the proliferative inhibition rates. The rates were increased gradually after the combination treatment, much higher than those treated with the corresponding concentration of As2O3 alone. The cells exhibited characteristics of mature granulocytes and a higher NBT-reducing ability, being a 2.6-fold increase in the rate of NBT-positive ratio of HL-60 cells within the As2O3 treatment versus almost a 13-fold increase in the TMP + As2O3 group. Cells treated with both TMP and As2O3 expressed far more CD11b antigens, almost 2-fold compared with the control group. Small doses of TMP potentiate As2O3-induced differentiation of HL-60 cells, possibly by regulating the expression and activity of G0/G1 phase-arresting molecules. Combination treatment of TMP with As2O3 has significant synergistic effects on the proliferative inhibition of HL-60 cells.
authors.affiliation: Key Laboratory of Developmental Diseases in Childhood, Department of Hematology, Affiliated Children’s Hospital, Chongqing Medical University, No. 136 Zhongshan 2nd Road, Yuzhong District, Chongqing, China. 198371lc@163.com
authors.forename: Yuni
authors.initials: Y
authors.lastname: Wu
authors.forename: Youhua
authors.initials: Y
authors.lastname: Xu
authors.forename: Yali
authors.initials: Y
authors.lastname: Shen
authors.forename: Cuicui
authors.initials: C
authors.lastname: Wang
authors.forename: Gaili
authors.initials: G
authors.lastname: Guo
authors.forename: Tiantian
authors.initials: T
authors.lastname: Hu
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000494:pharmacology*; D015153:Blotting, Western; D002453:Cell Cycle / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D004357:Drug Synergism; D005434:Flow Cytometry; D018922:HL-60 Cells / Q000166:cytology / Q000187:drug effects*; D006801:Humans; D010087:Oxides / Q000494:pharmacology*; D011719:Pyrazines / Q000494:pharmacology*; D020133:Reverse Transcriptase Polymerase Chain Reaction
chemical_list: D000970:Antineoplastic Agents; D001152:Arsenicals; D010087:Oxides; D011719:Pyrazines; D000077237:Arsenic Trioxide; C017953:tetramethylpyrazine